Biogen CEO Michel Vounatsos to Step Down After Aduhelm Controversies

May 3, 2022

Biogen has announced that Michel Vounatsos will resign from his position as CEO. This decision comes amidst layoffs and restructuring caused by the failure of Biogen’s Alzheimer’s drug Aduhelm. Among the reductions is the commercial group responsible for the drug’s development. Biogen is set to save over $500 million from the cuts.

According to the Biogen in an article by John Carroll of Endpoints News, “Increasing focus on R&D prioritization with the goal of maximizing the probability of success. This may include choosing to accelerate, terminate, divest, or partner certain programs, and will also include a continued evaluation of new internal and external opportunities within Biogen’s therapeutic areas of focus and adjacencies. “

To read more, click here.